TY - JOUR
T1 - Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias
T2 - Results from a European multinational epidemiological study
AU - Holl, Katsiaryna
AU - Nowakowski, Andrzej M
AU - Powell, Ned
AU - McCluggage, W Glenn
AU - Pirog, Edyta C
AU - Collas De Souza, Sabrina
AU - Tjalma, Wiebren A
AU - Rosenlund, Mats
AU - Fiander, Alison
AU - Castro Sánchez, Maria
AU - Damaskou, Vasileia
AU - Joura, Elmar A
AU - Kirschner, Benny
AU - Koiss, Robert
AU - O'Leary, John
AU - Quint, Wim
AU - Reich, Olaf
AU - Torné, Aureli
AU - Wells, Michael
AU - Rob, Lukas
AU - Kolomiets, Larisa
AU - Molijn, Anco
AU - Savicheva, Alevtina
AU - Shipitsyna, Elena
AU - Rosillon, Dominique
AU - Jenkins, David
N1 - © 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
PY - 2015/12/15
Y1 - 2015/12/15
N2 - Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.
AB - Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.
KW - Adult
KW - Aged
KW - Carcinoma, Adenosquamous
KW - Cervical Intraepithelial Neoplasia
KW - Cross-Sectional Studies
KW - Europe
KW - Female
KW - Human papillomavirus 16
KW - Humans
KW - Middle Aged
KW - Papillomavirus Infections
KW - Prevalence
KW - Retrospective Studies
KW - Uterine Cervical Neoplasms
KW - Young Adult
U2 - 10.1002/ijc.29651
DO - 10.1002/ijc.29651
M3 - Journal article
C2 - 26096203
SN - 0020-7136
VL - 137
SP - 2858
EP - 2868
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 12
ER -
